IN THE CLAIMS:

Please cancel claims 148, 159, 169, 180, 190, and 201.

This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

1-110. (Canceled)

111-146. (Not entered)

147. (Previously Presented) An isolated antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associated with binding of the chemokine to the receptor.

148. (Canceled)

149. (Canceled)

150. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

151. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

152. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

153. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

154. (Canceled)

155. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

156. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 147, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

157. (Canceled)

158. (Previously Presented) An isolated antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen binding fragment thereof additionally inhibits HIV infection.

159. (Canceled)

160. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

161. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

162. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

163. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

164. (Canceled)

165. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

166. (Previously Presented) The antibody or antigen binding fragment thereof of Claim 158, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

167. (Canceled)

168. (Previously Presented) A composition comprising:

an antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor; and

a physiologically acceptable vehicle or carrier.

169. (Canceled)

170. (Canceled)

171. (Previously Presented) The composition of Claim 168, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

172. (Previously Presented) The composition of Claim 168, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

173. (Previously Presented) The composition of Claim 168, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

174. (Previously Presented) The composition of Claim 168, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

175. (Canceled)

176. (Previously Presented) The composition of Claim 168, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

177. (Previously Presented) The composition of Claim 168, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

178. (Canceled)

179. (Previously Presented) A composition comprising:

an antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen binding fragment thereof additionally inhibits HIV infection; and

a physiologically acceptable vehicle or carrier.

180. (Canceled)

181. (Previously Presented) The composition of Claim 179, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

182. (Previously Presented) The composition of Claim 179, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

183. (Previously Presented) The composition of Claim 179, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

184. (Previously Presented) The composition of Claim 179, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

185. (Canceled)

186. (Previously Presented) The composition of Claim 179, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

187. (Previously Presented) The composition of Claim 179, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

188. (Canceled)

189. (Previously Presented) A test kit for use in detecting the presence of a human chemokine receptor 5 (CCR5) in a biological sample comprising:

a) an antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor; and

b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.

190. (Canceled)

191. (Canceled)

192. (Previously Presented) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

193. (Previously Presented) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

194. (Previously Presented) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

195. (Previously Presented) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

196. (Canceled)

197. (Previously Presented) The test kit of Claim 189, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

198. (Previously Presented) The test kit of Claim 189, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

199. (Canceled)

200. (Previously Presented) A test kit for use in detecting the presence of a human chemokine receptor 5 (CCR5) in a biological sample comprising:

a) an antibody or antigen binding fragment thereof which binds to the second extracellular loop of a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1α, MIP-1β, RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen binding fragment thereof additionally inhibits HIV infection; and

b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.

201. (Canceled)

202. (Previously Presented) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

203. (Previously Presented) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

204. (Previously Presented) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

205. (Previously Presented) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

206. (Canceled)

207. (Previously Presented) The test kit of Claim 200, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

208. (Previously Presented) The test kit of Claim 200, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, and Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

209. (Canceled)

210. (Canceled)